India markets open in 52 minutes
  • BSE SENSEX

    48,080.67
    +374.87 (+0.79%)
     
  • Nifty 50

    14,406.15
    +109.75 (+0.77%)
     
  • Dow

    33,815.90
    -321.41 (-0.94%)
     
  • Nasdaq

    13,818.41
    -131.81 (-0.94%)
     
  • BTC-INR

    3,743,707.50
    -342,458.50 (-8.38%)
     
  • CMC Crypto 200

    1,133.92
    -109.13 (-8.78%)
     
  • Hang Seng

    29,035.75
    +280.41 (+0.98%)
     
  • Nikkei

    28,983.31
    -204.86 (-0.70%)
     
  • EUR/INR

    90.3159
    +0.0413 (+0.05%)
     
  • GBP/INR

    104.0278
    +0.0910 (+0.09%)
     
  • AED/INR

    20.4050
    0.0000 (0.00%)
     
  • INR/JPY

    1.4342
    -0.0004 (-0.03%)
     
  • SGD/INR

    56.5080
    -0.0240 (-0.04%)
     

Global Asset Purchase Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014-2021 - ResearchAndMarkets.com

·4-min read

The "Global Asset Purchase Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014 to 2021" report has been added to ResearchAndMarkets.com's offering.

The Global Global Asset Purchase Deals in Pharma, Biotech and Diagnostics 2014-2020 report provides comprehensive access to available records for over 1,100 asset purchase deals, including contract documents where available.

The report provides a detailed understanding and analysis of how and why companies enter business, product, technology and royalty assets.

The focus of the report is on partnerships for business, product, technology and royalty assets where partners have entered an agreement to dispose of or acquire said assets.

Companies may seek to dispose of an asset simply because it is surplus to requirements. Or it may seek to dispose of assets in order to raise funds to invest in others parts of its business. Or it may be due to a regulatory requirement to dispose of certain business or product assets as a result of a pending business merger in order to meet competition regulations.

The report provides access to asset purchase deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.

The report focuses on four primary types of asset available for purchase:

  • Business assets - the most common asset exchanging hands. Business assets are in the form of a business unit or subsidiary of a parent company. Common assets include territorial businesses or non-core businesses such as an OTC or diagnostics business, separate from the core business operations

  • Product assets - in the form of marketed product, clinical phase development compound, or drug delivery-compound combination. These assets are commonly available as a result of a merger or change in direction of the selling company. The buyer acquires the asset for global or territorial exploitation. It is often the case that the acquiring company is normally a competitor to the seller, but in this situation the trade is of mutual benefit

  • Royalty assets - where a specialist investment company acquires the rights to future royalty payments in return for payment of a lump sum payment to the licensor for the product

  • Technology asset - where a buyer is acquiring a technology platform, research program, patent portfolio or other intellectual property asset. The acquisition is often due to the technology being surplus to a sellers interests, but may also be as a consequence of a sale of assets in advance of the seller entering liquidation

The report includes deals announced by hundreds of life science companies including big pharma such as Abbott, Abbvie, Actavis, Amgen, Astellas, AstraZeneca, Baxter, Bayer, Biogen Idec, BMS, Celgene, Eisai, Eli Lilly, Gilead, GSK, J&J, Kyowa Hakko, Merck, Mitsubishi, Mylan, Novartis, Pfizer, Roche, Sanofi, Shire, Takeda, Teva, and Valeant, amongst many others.

Key benefits

Global Asset Purchase Deals in Pharma, Biotech and Diagnostics 2014-2021 includes:

  • Trends in asset purchase dealmaking in the biopharma industry since 2014

  • Analysis of asset purchase deal structure

  • Case studies of real-life asset purchase deals

  • Access to over 1,100 asset purchase deal records

  • The leading asset purchase deals by value since 2014

  • Most active asset purchase dealmakers since 2014

  • The leading asset purchase partnering resources

Available deals are listed by:

  • Company A-Z

  • Headline value

  • Stage of development at signing

  • Therapeutic area

  • Technology type

Analyzing actual contract agreements allows assessment of the following:

  • What are the precise rights granted or optioned?

  • What is actually granted by the agreement to the partner company?

  • What exclusivity is granted?

  • What is the payment structure for the deal?

  • How are sales and payments audited?

  • What is the deal term?

  • How are the key terms of the agreement defined?

  • How are IPRs handled and owned?

  • Who is responsible for commercialization?

  • Who is responsible for development, supply, and manufacture?

  • How is confidentiality and publication managed?

  • How are disputes to be resolved?

  • Under what conditions can the deal be terminated?

  • What happens when there is a change of ownership?

  • What sublicensing and subcontracting provisions have been agreed?

  • Which boilerplate clauses does the company insist upon?

  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?

  • Which jurisdiction does the company insist upon for agreement law?

For more information about this report visit https://www.researchandmarkets.com/r/q0pauy

View source version on businesswire.com: https://www.businesswire.com/news/home/20210408005576/en/

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900